Updated NCCN Guidelines for the Treatment of Advanced or Recurrent Endometrial Cancer
Key opinion leaders review recent updates to the NCCN guidelines for treating recurrent and advanced endometrial cancer, including biomarker testing and targeted therapies like dostarlimab and trastuzumab.
Diagnosing and Staging Patients With Endometrial Cancer
Expert gynecologic oncologists discuss recent progress in treating advanced endometrial and cervical cancers, including epidemiology, risk factors, evaluation, staging, and molecular testing.
HRD Testing in Ovarian Cancer: Clinical Guidelines Recommendations
Panelists discuss clinical guidelines recommendations for HRD testing in ovarian cancer and how they inform their practice.
Leveraging HRD Testing Results in Ovarian Cancer: Clinical Data
Discussion centered around data from the PAOLA-1 trial, highlighting the prevalence of BRCA1/2 mutations and HRD status in ovarian cancer, and how patients with these alterations may benefit from PARP inhibitor treatment.
HRD Tests for Ovarian Cancer
The panel reviews commercially available HRD tests and expand upon factors that may influence test choice, such as clinical performance, institutional availability, turnaround time, and cost.
Other Causes of HRD: Chromosomal LOH, LST, and TAI
Dr Hagemann explains how loss of heterozygosity (LOH), large-scale state transitions (LSTs), and telomeric allelic imbalance (TAI) can also contribute to HRD.
Defining HRD and its Role in Ovarian Cancer
Experienced clinicians explain the role of the homologous recombination repair (HRR) pathway in DNA repair and how mutations in HRR-related genes, including BRCA1 and BRCA2, can cause homologous recombination deficiency (HRD) and contribute to the development and progression of ovarian cancer (OC).
Opening Remarks from Dr. Herzog, Dr. Krivak, and Dr. Hagemann
Thomas Herzog, MD, Thomas Krivak, MD, and Ian Hagemann, MD, PhD open their discussion by introducing themselves and the objectives of the program.
Dr. Krivak on the Importance of Germline Genetic Testing in Ovarian Cancer
Thomas C. Krivak, MD, discusses the importance of germline genetic testing in ovarian cancer.
Systemic Management of Ovarian Cancer: Closing Thoughts
Novel Combination Strategies in Recurrent Ovarian Cancer
Recurrent Ovarian Cancer: Novel Agents Under Investigation
Bevacizumab’s Role in Recurrent Ovarian Cancer
Recurrent Ovarian Cancer: Choosing a PARP Inhibitor
PARP Inhibition’s Role in Recurrent Ovarian Cancer
Frontline Ovarian Cancer Management: Ongoing Clinical Trials
Considerations for the JAVELIN OVARIAN 100 Study
Ovarian Cancer: Maintenance Following Frontline Bevacizumab
Ovarian Cancer: Updates to NCCN Guidelines
Treating Ovarian Cancer Based on HRD Status
Ovarian Cancer: What is the Role of HRD Testing?
Ovarian Cancer: Factors in Deciding on Maintenance Therapy
PAOLA-1: Combination Maintenance Therapy in Ovarian Cancer
Practical Applications of PRIMA in Ovarian Cancer Management
PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer
SOLO-1: Frontline Olaparib Maintenance Therapy in Ovarian Cancer
GOG-0218: Frontline Bevacizumab in Ovarian Cancer
Ribociclib Plus Endocrine Therapy Improves PFS and OS in Elderly Patients With HR+/HER2– Breast Cancer
Dr Ganesan on the Use of ctDNA Assays For MRD Detection in Cancer Care
Dr Habib on Developments in Palliative Care For Patients With Cancer
Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC
2 Clarke Drive Cranbury, NJ 08512